3 completed. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 1 | Completed 1 |
Follow apilimod: new trials by email Literature Review of apilimod trials Research Report on apilimod
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma LAM-002A, Rituximab, Atezolizumab - Lymphoma, Non-Hodgkin; Leukemia, Chronic Lymphocytic | Phase 1 | Completed | IRulya Therapeutics Inc. | 62 | 2015-10-01 | 2024-08-22 |
| STA-5326 Meslylate to Treat Gut Inflammation Associated With Common Variable Immunodeficiency STA-5326 - Common Variable Immunodeficiency | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 10 | 2005-12-02 | 2017-07-02 |
| STA-5326 in Crohn's Disease Patients STA-5326 - Crohn's Disease | Phase 1 / Phase 2 | Completed | Synta Pharmaceuticals Corp. | 48 | 2004-02-01 | 2005-06-24 |
Common Variable Immunodeficiency (1) · Crohn Disease (1) · Leukemia (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1) · Malabsorption Syndromes (1)
IRulya Therapeutics Inc. (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Synta Pharmaceuticals Corp. (1)
United States (3)